阿德福韦酯联合安络化纤丸治疗乙型肝炎肝硬化的疗效观察

目的观察阿德福韦酯（ADV）联合安络化纤丸治疗乙型肝炎肝硬化代偿期的疗效和安全性。方法 76例乙型肝炎代偿期肝硬化患者随机分为单用ADV的对照组及ADV＋安络化纤丸联合治疗的治疗组,两组患者疗程均为48周,治疗后观察两组患者肝功能、HBV及肝纤维化指标。结果治疗48周,联合治疗组肝功能均有好转,ALT、ALB及TBil与治疗前比较（P均〈0.05）,差异均有统计学意义。联合治疗组治疗后血清HBV DNA、HBe Ag低于检测下限的比率及HBe Ag/抗HBe转换率较治疗前升高,差异均有统计学意义（P均〈0.01）。联合治疗组肝纤维化各项指标下降值与对照组比较更显著（P均〈0.05）,差异均有统计学意义;其治疗后超声检测脾脏厚度及长径与治疗前比较均有减低,下降幅度与对照组比较更显著（P〈0.05）。结论 ADV联合安络化纤丸治疗乙型肝炎肝硬化有明显抗纤维化作用,其疗效优于单用ADV。

Clinical efficacy of adefovir dipivoxil combined with anluohuaxian pills on treating compensated cirrhosis patients with chronic hepatitis B

Objective To investigate the efficacy and safety of adefovir dipivoxil（ADV） combined with Anluohuaxian pills in treating HBV related compensated cirrhosis. Methods Total of 76 patients with compensated cirrhosis of hepatitis B virus infection were randomly assigned to treatment group（using ADV combined with Anluohuaxian pills） and control group（only using ADV）. The treatment lasted 48 weeks. And the liver function and index of HBV and liver fi brosis were observed after treatment. Results For treatment group, at week 48, the liver function were all better than before, and there were statistically significant difference in ALT, ALB and TBil between before and after treatment（P〈0.05）. Also there were statistically significant difference in HBV DNA negative rate, HBe Ag negative rate and HBe Ag seroconversion rate between before and after treatment（P〈0.01）. The decreased value of index of liver fibrosis were more obvious than those of the control group（P〈0.05）. The decreased value in ultrasonic inspection and measurement of spleen thickness and size of the treatment groups were more obvious than those of the control group（P〈0.05）. Conclusions ADV combined with Anluohuaxian pills in treatment HBV related-active cirrhosis can obviously anti-fi brosis and is better than solely using ADV.